Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits

被引:13
|
作者
Candas, B
Labrie, F
Gomez, JL
Cusan, L
Chevrette, E
Lévesque, J
Brousseau, G
机构
[1] Laval Univ Hosp, Mol Endocrinol & Oncol Res Ctr, Res Ctr, Ctr Hosp, Quebec City, PQ G1V 4G2, Canada
[2] Laval Univ Hosp, Dept Med, Res Ctr, Quebec City, PQ, Canada
[3] Laval Univ Hosp, Ctr Hosp, Prostate Canc Clin, Quebec City, PQ, Canada
[4] Univ Laval, Dept Physiol & Anat, Quebec City, PQ G1K 7P4, Canada
[5] Laval Univ Hosp, Dept Radiol, Res Ctr, Laval, PQ, Canada
来源
JOURNAL OF UROLOGY | 2006年 / 175卷 / 02期
关键词
prostate; prostatic neoplasms; mass screening; prostate-specific antigen;
D O I
10.1016/S0022-5347(05)00165-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the probability of positive serum PSA (3 ng/ml or greater) and CaP detection at annual followup visits in men with negative initial PSA (less than 3 ng/ml) to optimize the re-screening schedule. Materials and Methods: Data on 5,387 men 45 to 80 years old with negative PSA and no CaP diagnosis at the first screening visit were obtained from the Laval University Prostate Cancer Screening Program database. Accelerated failure time regressions were fitted to time from baseline to positive PSA and to time from positive PSA to CaP detection. The models were combined to estimate the cumulative probability of positive PSA followed by CaP detection at re-screening. Results: The 5-year cumulative probability of detecting CaP at annual visits in men with baseline PSA up to 1.5 ng/ml remained below 0.8%, while it was 1.3%, 4.8% and 8.3% in men with PSA 1.5 to less than 2, 2 to less than 2.5 and 2.5 to less than 3 ng/ml, respectively. Time to positive PSA significantly decreased with increasing baseline PSA and age, while the time between positive PSA and CaP detection depended only on age. Men with PSA below 1.0 ng/ml could wait for 4 to 5 years before being re-tested, while men with PSA between 1.0 and 1.5 ng/ml should be screened every second year and men with PSA 1.5 ng/ml or greater should be screened every year. Conclusions: The proposed retesting schedule using current PSA and age decreases the number of visits by 38.1%, while delaying the detection of only 2.4% of CaPs that would have been detected using annual PSA testing.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 50 条
  • [41] Serum prostate-specific antigen screening for prostate cancer: Analysis of the costs and benefits
    Mermershtain, W.
    Bone, D.
    Shteiman, T.
    Ariad, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] SERUM PROSTATE SPECIFIC ANTIGEN AS PRE-SCREENING TEST FOR PROSTATE-CANCER
    LABRIE, F
    DUPONT, A
    SUBURU, R
    CUSAN, L
    TREMBLAY, M
    GOMEZ, JL
    EMOND, J
    STAMEY, TA
    LANGE, PH
    JOURNAL OF UROLOGY, 1992, 147 (03): : 846 - 852
  • [43] A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer
    Palma, Anton
    Lounsbury, David W.
    Schlecht, Nicolas F.
    Agalliu, Ilir
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2016, 183 (03) : 227 - 236
  • [44] A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
    Catalona, William J.
    Partin, Alan W.
    Sanda, Martin G.
    Wei, John T.
    Klee, George G.
    Bangma, Chris H.
    Slawin, Kevin M.
    Marks, Leonard S.
    Loeb, Stacy
    Broyles, Dennis L.
    Shin, Sanghyuk S.
    Cruz, Amabelle B.
    Chan, Daniel W.
    Sokoll, Lori J.
    Roberts, William L.
    van Schaik, Ron H. N.
    Mizrahi, Isaac A.
    JOURNAL OF UROLOGY, 2011, 185 (05): : 1650 - 1655
  • [45] Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression
    Akbay, Erdem
    Bozlu, Murat
    Cayan, Selahittin
    Kara, Pelin Ozcan
    Tek, Mesut
    Aytekin, Cuma
    AGING MALE, 2017, 20 (03): : 175 - 183
  • [46] The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer
    Eric A. Miller
    Paul F. Pinsky
    Dudith Pierre-Victor
    Cancer Causes & Control, 2018, 29 : 907 - 914
  • [47] The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer
    Miller, Eric A.
    Pinsky, Paul F.
    Pierre-Victor, Dudith
    CANCER CAUSES & CONTROL, 2018, 29 (10) : 907 - 914
  • [48] Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer
    Ellis, WJ
    Etzioni, R
    Vessella, RL
    Hu, CC
    Goodman, GE
    JOURNAL OF UROLOGY, 2001, 166 (01): : 93 - 98
  • [49] Urinary/serum prostate-specific antigen ratio:: Comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection
    Irani, J
    Salomon, L
    Soulié, M
    Zlotta, A
    de la Taille, A
    Doré, B
    Millet, C
    UROLOGY, 2005, 65 (03) : 533 - 537
  • [50] Prostate-specific antigen in the early detection of prostate cancer
    Thompson, Ian M.
    Ankerst, Donna P.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (13) : 1853 - 1858